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ABSTRACT
Objective. Sevoflurane has been used in 
cardiac surgery because of its protective ef-
fects on the myocardium from ischaemic 
injury. We wanted to test the hypothesis 
that sevoflurane has beneficial effects on 
the heart and kidneys in comparison to 
propofol.
Methods. We conducted a randomised 
controlled study, with balanced randomi-
zation blocked by sex. The participants 
were 62 patients undergoing off-pump 
myocardial revascularization (44 men and 
18 women), who did not have a myocardi-
al infarction less than 24 hours before the 
start of the operation and who had normal 
serum values of troponin I preoperatively. 
The surgery and the measurements were 
conducted according to the same protocol 
for both groups. Propofol was used for the 
induction of anaesthesia in both groups; 
anaesthesia was continued with either 
propofol or sevoflurane. Troponin I and 
cystatin C plasma concentrations were de-
termined in eight consecutive blood sam-
ples, starting before induction of anaesthe-
sia and ending 48 hours after admission 
to the intensive care unit (ICU). The data 
were log-transformed and analysed using 
analysis of variance.
Results. We observed a clear and highly 
statistically significant effect of time for 
troponin I (p<0.001) without statistically 
significant differences between the groups 
(either main or interaction effects). For the 
majority of patients, the measurements 
rose quickly upon reperfusion and reached 
a peak 12 hours after admission to the ICU, 
descending approximately back to the rep-
erfusion level 48 hours after admission to 
the ICU. Similar inferences were reached 
for cystatin C, for which the time-course 
was approximately bath-shaped.
Conclusion. We observed no clear superi-
ority of either sevoflurane or propofol an-
aesthetic regime in off-pump myocardial 
revascularisation.
Key words: anaesthetic regime, cardiopro-
tection, kidney function, heart surgery
INTRODUCTION
Perioperative myocardial ischaemia can 
increase morbidity and mortality after 
cardiac surgery. To prevent or lessen myo-
cardial ischaemia during and after surgery, 
various approaches have been proposed 
that are directed towards modulation of 
the myocardial oxygen supply-demand re-
lationship. (1)
The protective mechanism of ischaemic 
preconditioning might greatly exacerbate 
the ischaemia symptoms of an already in-
jured heart. (2) With the use of halogenated 
anaesthetics, anaesthetic preconditioning 
can be achieved, mimicking the protective 
role of ischaemic preconditioning and pro-
voking the adaptive responses of the myo-
cardium to ischaemic insult. (3-7)
The protective effect of sevoflurane is most 
apparent (8-10) when applied throughout 
coronary artery bypass surgery, with the 
use of cardiopulmonary bypass (CPB) in 
a certain minimal alveolar concentration 
(MAC) range. It has also been reported 
that the use of sevoflurane in an anaesthet-
ic regime reduces postoperative morbidity 
and mortality. (11)
Acute kidney injury is a major periop-
erative complication after cardiac sur-
gery, which is associated with significant 
morbidity, mortality and related costs. 
(12) After sevoflurane preconditioning, 
postoperative kidney function can be pre-
served in patients undergoing coronary 
artery bypass graft surgery under CPB, as 
demonstrated by a lower serum cystatin C 
level. (13)
Based on the findings summarised above, 
we conducted a study testing the hypoth-
esis that sevoflurane protects the heart and 
the kidneys in comparison to propofol in 
off-pump heart surgery. Cardioprotection 
was assessed during and after the opera-
tion by the release of troponin I, the bio-
chemical marker of myocardial ischemia. 
Kidney function was monitored via cysta-
tin C serum levels at the same time-points 
as troponin I levels.
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METHODS
Patients
The study was registered with the Health 
Insurance Institute of Slovenia (registra-
tion no. 20100301, principal investigator 
Nina Kosmač, date of registration 5th No-
vember, 2009, trial duration 2010-2012). 
The national legislation and local research 
practice guidelines did not require or rec-
ommend international registration at the 
time of study design, registration and ethi-
cal approval. The study was approved by 
the National Medical Ethics Committee of 
the Republic of Slovenia (http://www.kme-
nmec.si/) on 31 December 2009 (research 
no. 95/11/09) as a continuation of previ-
ously approved research (no. 82/05/04 and 
92/01/06). All patients gave informed con-
sent, were aged 18 years or older, and had 
ischaemic heart disease without valvular 
disease.
We conducted a randomised clinical trial. 
It was performed prospectively in patients 
scheduled for off-pump heart surgery. 
None of the patients had myocardial in-
farction less than 24 hours before the start 
of surgery and all patients had normal se-
rum values of troponin I preoperatively.
Balanced computerised randomisation 
was employed, which involved 62 patients 
(44 men and 18 women), so that there were 
31 patients in each group. Because ran-
domisation was blocked by sex, there were 
22 men and 9 women in each group. The 
patient recruitment process is summarised 
in figure 1.
Figure 1. Flow-chart of patient recruitment.
Figure 2. Distributions of troponin I meas-
urements.
Notes: vertical axis is in logarithmic scale 
in order to show the variables as they were 
entered into the ANOVA models; box-
plots: thick line – median; box – interquar-
tile range; whiskers – non-outlier range; 
circles – outliers; asterisks – extremes.
Figure 3. Distributions of cystatin C meas-
urements.
Notes: vertical axis is in logarithmic scale 
in order to show the variables as they were 
entered into the ANOVA models; box-
plots: thick line – median; box – interquar-
tile range; whiskers – non-outlier range; 
circles – outliers; asterisks – extremes.
Figure 4. Distributions of the calculated pa-
rameters summarising the time-course of 
the measurements.
Notes: vertical axis is in logarithmic scale 
in order to show the variables as they were 
entered into the ANOVA models; box-
plots: thick line – median; box – interquar-
tile range; whiskers – non-outlier range; 
circles – outliers; asterisks – extremes.
Anaesthesia and surgical procedure
Anaesthesia and surgery were conducted 
similarly in both groups except for the 
maintenance of general anaesthesia. All 
preoperative heart medications were con-
tinued until the morning of the surgery, 
with the exception of angiotensin-convert-
ing-enzyme inhibitors. All patients fasted 
from midnight. Bromazepam 1.5-3.0 mg 
was given to patients on the evening be-
fore the operation and in the morning on 
the day of the operation, unless the patient 
had already been taking alprazolam at 
home; in the latter case, 0.5 mg alprazolam 
was given in the evening and 0.25 mg in 
the morning. In addition, a proton-pump 
inhibitor (pantoprazole or omeprazole) 
was administered in the morning before 
the operation. After premedication on the 
ward, the patients were admitted to the an-
aesthetic room. A peripheral venous line 
was inserted and an arterial line was placed 
in the radial artery..
Propofol was used for induction of anaes-
thesia by continuous infusion of 10 mg/kg 
body weight (BW)/h, which was changed 
to 3-5 mg/kg BW/h after 2 minutes, after 
which midazolam (1 to 2 mg) and fentanyl 
(by boluses of 5 to 7 μg/kg BW) were add-
ed. Vecuronium 0.1 mg/kg BW was used 
for muscular relaxation in all patients. 
Patients were intubated and mechanically 
ventilated with oxygen-air mixture (FiO2 
0.4). In the sevoflurane group, the infu-
sion of propofol was stopped after intuba-
tion, and anaesthesia was maintained with 
sevoflurane 1 to 1.5 MAC. In the propofol 
group, we continued with an infusion of 
propofol 3-5 mg/kg BW/h. The selected 
anaesthetic regime was used throughout 
the operation. After induction of anaesthe-
sia, a central venous line and urinary cath-
eter were inserted in all patients.
We gave 1 mg/kg of heparin to achieve an 
activated coagulation time (ACT) of 250 
seconds or more before the surgeon com-
menced the sewing of anastomoses and 
manipulations of the heart. At the end of 
the operation, heparin was neutralised 
with protamine sulphate according to the 
1:0.8 ratio (i.e., 0.8 mg protamine for 100 
IE heparin), until the pre-anaesthesia ACT 
was reached. Surgical access to the heart 
was always via a sternotomy incision. The 
left internal mammary artery was dis-
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placed from the thoracic wall to perform 
the bypass on the left coronary artery 
(LAD) or its branches, and the saphenous 
vein taken. All the off-pump procedures 
were performed by the same surgeon (the 
fifth author) and the anaesthesiologist was 
also always the same person (the first au-
thor).
We directly monitored arterial pressure, 
central venous pressure, urine output per 
hour, 12 channel ECG, temperature, FiO2, 
capnography, blood gasses and pulse ox-
ymetry during surgery in all patients. 
Haemodynamic monitoring included the 
Advanced Minimally Invasive Monitoring 
(Edwards Lifesciences). When used with 
Flo-Trac sensor and Pre-Sep catheter, the 
Vigileo monitor measures and displays key 
flow parameters (Cardiac output – CO, 
Stroke volume – SV, Stroke volume vari-
ation – SVV, Systemic vascular resistance 
– SVR) and continuous central venous 
oxygen saturation (ScvO2), thus being a 
single-monitor solution for fluid optimisa-
tion and tissue oxygenation.
If the patients showed signs of systemic 
hypotension during the manipulations of 
the heart, we first directed the surgeon’s 
attention to it;communication between 
the surgeon and the anaesthesiologist is es-
sential during off-pump heart surgery. The 
surgeon would then reposition the heart 
and wait for the patient to stabilise. Then 
we would infuse fluids or blood if needed, 
or give vasoactive or inotropic and antiar-
rhythmic drugs. There was no need to ini-
tiate CPB in any patient.
After the operation, propofol and sevo-
flurane were discontinued and patients 
were transferred to the intensive care unit 
(ICU). Fast-tracked awakening and extu-
bation followed. Patients were given fenta-
nyl during the operation for analgesia, and 
piritramide 45 mg/50 ml infusion 2.3 ml/
hour (as well as paracetamol 1 g/8 hours 
if needed) in the ICU. All patients were 
weaned from the respirator and extubated 
within 6 hours of the end of the operation 
and transfer to the ICU. There were no 
reoperations because of bleeding or any 
other complications.
Blood samples and biochemical analy-
ses
To quantify ischaemic myocardial injury, 
we measured troponin I (ADIVA Centaur 
XP, Siemens, Germany). Cystatin C was 
determined to indicate renal dysfunction 
(cystatin C ELISA test). All analyses were 
performed at the Clinical Institute for 
Chemistry and Biochemistry of the Uni-
versity Medical Centre Ljubljana. Blood 
samples were taken at the following eight 
time-points:
 ■ before induction of anaesthesia;
 ■ during cross-section of the pericar-
dium;
 ■ upon completion of the distal coronary 
anastomoses;
 ■ upon reperfusion;
 ■ 30 minutes after admission to the ICU;
 ■ 12 hours after admission to the ICU;
 ■ 24 hours after admission to the ICU;
 ■ 48 hours after admission to the ICU.
Statistical analyses
The sample size for the study was deter-
mined based on a simplistic univariate 
analysis aiming to prove a difference be-
tween the two groups of 0.25 μg/L in the 
average troponin I value at a selected time-
point with 80% power at 5% alpha level, 
assuming a standard deviation of 0.35 μg/L 
within each group.
We first tested the successfulness of ran-
domisation by comparing relevant base-
line characteristics (age, LVEF – left ven-
tricular ejection function, EURO score and 
weight) using the independent-samples 
t-test. In the main analyses of both blood 
parameters we tested the differences be-
tween the two groups of the mean values 
over time using the mixed-model analysis 
of variance (ANOVA). Before ANOVA, 
the measurements were log-transformed, 
which reduced the asymmetry of the dis-
tributions and homogenised the variances. 
We first conducted three-way 2×2×8 
ANOVA, whereby group and sex were 
the between-subject (with 2 levels each) 
factors and time was the within-subject 
factor (with 8 levels). Because neither the 
main effect of sex nor the interaction ef-
fects including sex were statistically sig-
nificant, we subsequently pooled the men 
and women and conducted a two-way 2×8 
ANOVA (with group and time as the fac-
tors). Whenever Mauchly’s test indicated 
statistically significant departure from the 
assumption of sphericity, the Greenhouse-
Geisser correction was applied to the tests 
of within-subject effects (as evidenced by 
non-integer degrees of freedom, df, re-
ported in the results). We did not conduct 
post-hoc analyses after ANOVA, but we 
tested for trend over time using polyno-
mial contrasts.
We also summarised the time-course with 
two parameters for each analysed sub-
stance for each patient. For troponin I, we 
calculated the range (i.e., the difference be-
tween the highest and the lowest measure-
ment), and the ratio between the 6th and 
the 4th measurement (when the largest 
rise typically occurs). For cystatin C, we 
calculated the median and the range. We 
analysed those parameters using two-way 
between-subjects 2×2 ANOVA with group 
and sex as the two factors.
 ■ Statistical significance was set at p≤0.05.
 ■ Statistical analyses were performed us-
ing IBM SPSS Statistics for Windows 20 
(IBM Corp., Armonk, NY, 2011).
RESULTS
The baseline characteristics of the patients 
are summarised in table 1. The lack of sta-
tistically significant differences indicates 
that randomisation was successful and that 
the two groups could be validly compared.
The distributions of the measurements are 
depicted in figures 2 and 3 for troponin I 
and cystatin C, respectively. The mixed-
model analyses of variance are summarised 
in table 2.
The lack of a statistically significant effect 
of sex (F1,58=0.19, p=0.666 for troponin 
and F1,58=2.95, p=0.091 for cystatin C) 
or any of the interactions involving sex 
(group×sex: F1,58=0.96, p=0.331 for tro-
ponin and F1,58=3.53, p=0.065 for cystatin 
C; time×sex: F2.71,157.21=0.84, p=0.466 
for troponin and F3.73,216.21=0.85, 
p=0.487 for cystatin C; time×group×sex: 
F2.71,157.21=0.30, p=0.804 for troponin 
and F3.73,216.21=0.32, p=0.853 for cysta-
tin C) justified its omission as a factor from 
further analyses. The effect of time proved 
to be highly statistically significant for both 
blood parameters (F2.71,157.21=201.48, 
p<0.001 for troponin; F3.73,216.21=6.37, 
p<0.001 for cystatin C). For the majority of 
patients, the troponin I measurements re-
mained at the initial level until reperfusion, 
then rose quickly and reached a peak 12 
hours after admission to the ICU, descend-
ing approximately back to the reperfusion 
level 48 hours after admission to the ICU. 
For cystatin C, the time-course was rough-
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ly the opposite, thus approximately bath-
shaped, only with relatively smaller chang-
es. For both blood parameters, quadratic 
contrasts were statistically significant for 
time (F1,58=106.83, p<0.001 for troponin 
and F1,58=28.82, p<0.001 for cystatin C).
For the calculated parameters, distribu-
tions are depicted in figure 4 and the analy-
ses of variance are summarised in table 3. 
No statistically significant effect was found 
(all p-values were >0.05; F statistics, asso-
ciated degrees of freedom and p-values are 
listed in table 3). 
Table 1. Baseline characteristics of the two patient groups.
Characteristic Sevoflurane group Propofol group p
Age [years; mean (SD)] 67.1 (10.0) 65.2 (9.7) 0.450
LVEF [%; mean (SD)] 49% (14%) 53% (11%) 0.305
LVEF [no. with deteriorated / 
normal heart function]
6 / 25 7 / 24 1.000
euroSCORE [points; mean (SD)] 2.1% (2.0%) 1.9% (2.0%) 0.805
Weight [kg; mean (SD)] 86.2(19.6) 80.3(14.9) 0.188
Sex [no. female / male] 9 / 22 9 / 22 NA
LVEF, left ventricular ejection function; NA, not applicable (balanced by design).
Table 2. Summary of the mixed-model analyses of variance for the measurements.
Blood parameter Model Effect p








































Table 3. Summary of the two-way between-subjects analyses of variance for the calculated parameters.
Blood parameter Calculated parameter Effect F df p
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Our randomised trial compared the effect 
of sevoflurane- and propofol-maintained 
anaesthesia on troponin I and cystatin C 
concentrations in patients undergoing off-
pump heart surgery.
The study was balanced by sex and no 
statistically significant influence of sex on 
the release of either troponin I or cystatin 
C was observed. Women had long been 
excluded from such clinical trials because 
coronary artery disease had been a men’s 
domain; but it was shown that female sex 
is associated with increased length of stay 
after coronary artery bypass surgery be-
cause of the advanced age at which women 
face coronary disease, higher incidence of 
comorbidities compared with men when 
they need bypass surgery, lower body size 
and narrower coronary vessels with diffi-
cult access. (14-15) There may be a differ-
ence in myocardial structural proteins be-
tween the sexes, and hence a difference in 
response to ischaemia and reperfusion in-
jury. Schwarzenberger and co-workers ob-
served greater release of troponin I in men 
than in women during on-pump coronary 
artery bypass surgery. (16) Women also 
wake faster following general anaesthesia 
and differ from men in their postoperative 
recovery as reflected by postoperative pain, 
nausea and vomiting, and overall quality of 
recovery. Female sex hormones may play a 
role in modulating the beneficial and ad-
verse effects of general anaesthesia. (17) 
Nevertheless, we observed no clear dif-
ferences between men and women in our 
study, and therefore pooled them for sub-
sequent analyses in order to gain statistical 
power.
No statistically significant difference was 
found between the two anaesthetic regimes 
either in the overall level of blood param-
eters (which would correspond to the 
main effect of the group) or in the shape 
of the time-course of the blood parameters 
(which would correspond to a group×time 
interaction effect). The analyses of the cal-
culated parameters, which might efficiently 
summarise the time-course and reduce the 
random inter-patient variation, confirmed 
this finding. According to De Hert and co-
workers, (8) the anaesthetic regime used in 
our study was most protective throughout 
the surgical procedure. De Hert also high-
lighted that the relationship between the 
dose of volatile anaesthetic that is sufficient 
to provide general anaesthesia and the dose 
that could provide protection from ischae-
mic injury, as well as the exact time of ad-
ministration to achieve cardioprotection, 
is still not known, whereby a prohibitively 
high number of patients would be needed 
to resolve those questions. (18). Similarly, 
a recent systematic review pointed out 
that not all studies have demonstrated im-
proved outcomes as a result of using vola-
tile anaesthetics as cardioprotective agents 
in patients undergoing coronary artery by-
pass graft surgery. (19)
Conzen and co-workers used the principle 
of the two regimes of anaesthesia through-
out the procedure in off pump heart sur-
gery and observed lower troponin I release 
as well as diminished inflammatory pro-
cess when sevoflurane was administered. 
(20) Landoni and co-workers reviewed 
the protective role of volatile anaesthetics 
desflurane and sevoflurane in randomised 
clinical trials and argued that volatile an-
aesthetics could reduce the postoperative 
release of cardiac troponin I, the need for 
inotropic support, and the number of pa-
tients requiring prolonged hospitalisation 
following coronary artery bypass graft sur-
gery either with or without cardiopulmo-
nary bypass. (11)
Off-pump heart surgery is associated with 
lower risk of developing acute kidney in-
jury than on-pump heart surgery, and may 
be one of the factors that offer better sur-
vival outcomes after coronary artery sur-
gery. The risk of death increases with the 
rising degree of renal injury . (21,22) The 
overall index of kidney function is pro-
vided by glomerular filtration rate (GFR). 
Cystatin C has been suggested to be an 
endogenous marker of GFR. It does not 
change with age or muscle mass and is not 
influenced by protein in the diet. However, 
a study has demonstrated that older age is 
associated with higher serum cystatin C 
levels. (23) Stevens and co-workers sug-
gest that serum cystatin C may be a better 
predictor of outcomes of cardiovascular 
disease than GFR estimates based on levels 
of serum creatinine. (23-24) Serum cysta-
tin C concentration is related to weight and 
height as well as to smoking status and C-
reactive protein and steroid presence, rises 
proportionally when GFR decreases and is 
susceptible to small deteriorations in renal 
function. (23-24)
In our study a shallow bath shape of the 
time-course of cystatin serum concen-
tration was observed in both groups. 
Somewhat higher, but not statistically sig-
nificantly, average cystatin C values were 
observed in the sevoflurane group (in 
which two patients had very high values). 
Most importantly, all the observed values 
of cystatin C were within the normal range 
for all patients, thus suggesting mainte-
nance of normal kidney function during 
and after myocardial revascularisation on 
the beating heart.
Vives concluded that acute kidney injury 
was a major perioperative complication 
after cardiac surgery, associated with sig-
nificant morbidity and mortality and relat-
ed costs, but no preventive strategies had 
been suggested. Early treatment with renal 
replacement therapy may improve out-
comes after heart surgery. (12) Seabra and 
co-workers published results of a meta-
analysis of 22 trials comparing on-pump 
to off-pump heart surgery regarding acute 
kidney injury, and found that off-pump 
surgery might be associated with a lower 
incidence of acute kidney injury but had 
no effect on dialysis requirement or all-
cause mortality. (26)
To summarise, we were unable to confirm 
the hypothesis that sevoflurane protects 
the heart more effectively than propofol 
in myocardial revascularisation without 
the use of cardiopulmonary bypass. Our 
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patients were all aged about 65 years, had 
good ventricular function and a low EURO 
score. It is likely that the characteristics of 
the patients in our sample precluded the 
possibility of detecting a substantial differ-
ence between the two anaesthetic regimes 
concerning either myocardial or kidney 
function. It should also be emphasised 
that all patients were operated by the same 
surgeon and that the anaesthesiologist was 
also the same in all cases.
Hence, our randomised trial showed no 
clear superiority of either the sevoflurane 
or propofol anaesthetic regime in off-
pump myocardial revascularisation in re-
gard to either heart protection, as reflected 
in troponin I concentration, or kidney pro-
tection, as reflected in cystatin-C concen-
tration. We therefore support both options 
for future clinical use.
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